Arkolith/Insider Trading/VIVO/Form 4

Weltzien Lourdes

Executive VP, Life ScienceMERIDIAN BIOSCIENCE INC (VIVO) · full profile →Form 4 · filed Jan 31, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
2 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 31, 2023Disposed to issuer(D)86K——0
Jan 31, 2023Grant(A)8K——86K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 31, 2023Disposed to issuer(D)12K$15.12$176K0
Jan 31, 2023Disposed to issuer(D)12K$15.52$188K0
Jan 31, 2023Disposed to issuer(D)3K$19.70$49K0
Jan 31, 2023Disposed to issuer(D)10K$14.34$143K0

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001567619-23-001528) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML